Review




Structured Review

Sequenom massarray methylation detection
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Methylation Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/massarray+quantitative+methylation+analysis/pmc09085879-231-0-4
Average 90 stars, based on 1 article reviews
massarray methylation detection - by Bioz Stars, 2026-09
90/100 stars

Images

1) Product Images from "DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334"

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

Journal: Cell Death & Disease

doi: 10.1038/s41419-022-04895-6

A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Figure Legend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Techniques Used: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing

Related Articles

Methylation:

Article Title: Gender dimorphism in hepatocarcinogenesis—DNA methylation modification regulated X‐chromosome inactivation escape molecule XIST
Article Snippet: .. Methylation of CpG sites of the Xist first exon region in liver tissues between 10 WT and 10 Tet2 −/− female mice was quantified by Sequenom MassARRAY methylation profiling. ..

Article Title: Gender dimorphism in hepatocarcinogenesis—DNA methylation modification regulated X‐chromosome inactivation escape molecule XIST
Article Snippet: .. Methylation of XIST was detected by Sequenom MassARRAY methylation profiling between HCC tissues (T) and adjacent normal liver tissues (L). ..

Article Title: Exposure to Juvenile Stress Induces Epigenetic Alterations in the GABAergic System in Rats.
Article Snippet: .. Sequenom Epityper MassARRAY Methylation and Spectra Analysis Samples were desalted and spotted on a 384-alternative patch SpectroCHIP (Se- quenom, San Diego, CA, USA) using the MassARRAY nanodispenser, and spectra were analyzed by the MassARRAY Analyzer Compact matrix-assisted laser desorption/ioniza- tion–time of flight (MALDI-TOF MS) (Sequenom, San Diego, CA, USA). .. Spectra were elaborated by the Epityper 1.2 software (Sequenom, San Diego, CA, USA), which provides methylation values for each CpG unit as a percentage.

Article Title: DNA Hyper-methylation Associated With Schizophrenia May Lead to Increased Levels of Autoantibodies
Article Snippet: .. A Sequenom MassARRAY quantitative methylation assay was performed to measure the methylation levels of candidate DMS cg14341177 and cg13978347 in the discovery cohort. .. There are 4 CpG sites on cg14341177, in which the CpG2 site showed the most significant changes in methylation levels and seemed as the leading CpG site.

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..

other:

Article Title: Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis
Article Snippet: The methylation profiling was validated by two methods including Illumina-sequencing-based BSP and Sequenom MassARRAY® Methylation.

Article Title: Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.
Article Snippet: For participants with methylation data, technical replication (see Technical replication of DNA methylation profiling in Additional file 1) was conducted: 194 participants were randomly chosen for Illumina sequencing-based BSP detection to verify the chip detection site results, and among these 194 participants, 20 were further randomly selected to undergo Sequenom MassARRAY® Methylation validation.

Expressing:

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..

Western Blot:

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..

Real-time Polymerase Chain Reaction:

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..

Agarose Gel Electrophoresis:

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..

Methylated DNA Immunoprecipitation:

Article Title: Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST.
Article Snippet: .. Scale bar, 50 μm. (G and H) The expression of YY1 in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by western blot analysis. (I) Expression of YY1 and XIST in HCC-1016 cells (knocked down YY1 in HCC-1016 cells by transfecting siRNA) by qPCR. (J) XIST was quantified using DNA agarose gel electrophoresis. (K) The 5-methylcytosine (5mC) level in the XIST promoter region by MeDIP assay and qPCR. was quantified by Sequenom MassARRAY methylation profiling. ..



Similar Products

96
agena bioscience agena massarray methylation detection
Agena Massarray Methylation Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/ppr0552502-125-0-0
Average 96 stars, based on 1 article reviews
agena massarray methylation detection - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

90
Sequenom massarray methylation detection
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Methylation Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/massarray+quantitative+methylation+analysis/pmc09085879-231-0-4
Average 90 stars, based on 1 article reviews
massarray methylation detection - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

96
agena bioscience massarray system methylation detection amplification pcr reaction
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/pm31002356-111-8-15
Average 96 stars, based on 1 article reviews
massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

96
agena bioscience agena massarray system methylation detection amplification pcr reaction
A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Agena Massarray System Methylation Detection Amplification Pcr Reaction, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+methylation+detection/Methylation/pm31002356-111-7-15
Average 96 stars, based on 1 article reviews
agena massarray system methylation detection amplification pcr reaction - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

Image Search Results


A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: MassARRAY methylation detection technology (Sequenom, USA) performed by CapitalBio Technology (Shanghai, China) was used to detect the methylation level of ZNF334 promoter (human) in carcinoma and paracancerous tissues of 25 HCC patients and Zfp334 promoter (mice) in treatment and control group.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing